PharmaBoardroom

Patents & Trademarks: China

An outline of the legal situation around patents and trademarks for pharmaceuticals in China. Prepared in association with Fangda Partners, one of…

Product Liability: China

A comprehensive guide to the legal implications around product liability in China. Prepared in association with Fangda Partners, one of China’s…

Traditional Medicines and OTC Products: China

A legal intro to traditional medicines and OTC products in China. Prepared in association with Fangda Partners, one of China’s most prestigious and…

Marketing, Manufacturing, Packaging & Labeling, Advertising:…

A brief overview of the situation regarding marketing, manufacturing, packaging & labeling and advertising within Chinese pharma. Prepared in…

Preclinical and Clinical Trial Requirements: China

The essential requirements for conducting preclinical and clinical trials in China. Prepared in association with Fangda Partners, one of China’s…

Regulatory, Pricing and Reimbursement: China

An intro to the regulatory, pricing and reimbursement scenario for pharmaceuticals in China. Prepared in association with Fangda Partners, one of…

Top 2021 Insights from Global Regulators

Over the past 12 months, PharmaBoardroom has spoken to the heads of several key regulatory bodies across the world. While the approval processes for…

Vinod Narayanan – Country President, AstraZeneca Singapore

AstraZeneca (AZ)’s country president for Singapore, Vinod Narayanan, outlines the challenges of taking the reins at an affiliate against the…

Lars Bo Nielsen – Director General, Danish Medicines Agency

In a wide-ranging interview, incoming director general of the Danish Medicines Agency Lars Bo Nielsen discusses the challenges that personalised…

Is Everything So Wrong at GSK?

British pharmaceuticals giant, GSK, one of the UK’s largest companies by market capitalization, is once again finding itself under the spotlight as…

China Strives for First-In-Class Drug Innovation with New Patent…

In a comprehensive new piece, European Patent Attorney André Bourgouin and Adjunct Professor at CEIBS Eric Bouteiller examine the potential impact of…

Italy’s Market Access Reform: A Watershed Moment?

In recent months, a profound transformation has been occurring right at the core of the Italian pharmaceutical industry as the most significant…

Tagged with EG